GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (STU:CU2) » Definitions » Cyclically Adjusted Revenue per Share

Cerus (STU:CU2) Cyclically Adjusted Revenue per Share : €0.58 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Cerus Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cerus's adjusted revenue per share for the three months ended in Mar. 2024 was €0.194. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.58 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Cerus's average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cerus was 6.90% per year. The lowest was -9.40% per year. And the median was 2.40% per year.

As of today (2024-05-22), Cerus's current stock price is €1.804. Cerus's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.58. Cerus's Cyclically Adjusted PS Ratio of today is 3.11.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cerus was 14.94. The lowest was 1.95. And the median was 8.35.


Cerus Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Cerus's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Cyclically Adjusted Revenue per Share Chart

Cerus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.46 0.51 0.57 0.63

Cerus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.58 0.59 0.63 0.58

Competitive Comparison of Cerus's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Cerus's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cerus's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cerus's Cyclically Adjusted PS Ratio falls into.



Cerus Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cerus's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.194/131.7762*131.7762
=0.194

Current CPI (Mar. 2024) = 131.7762.

Cerus Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.085 100.560 0.111
201409 0.106 100.428 0.139
201412 0.097 99.070 0.129
201503 0.075 99.621 0.099
201506 0.082 100.684 0.107
201509 0.073 100.392 0.096
201512 0.090 99.792 0.119
201603 0.069 100.470 0.090
201606 0.081 101.688 0.105
201609 0.088 101.861 0.114
201612 0.093 101.863 0.120
201703 0.063 102.862 0.081
201706 0.081 103.349 0.103
201709 0.082 104.136 0.104
201712 0.120 104.011 0.152
201803 0.088 105.290 0.110
201806 0.100 106.317 0.124
201809 0.098 106.507 0.121
201812 0.107 105.998 0.133
201903 0.113 107.251 0.139
201906 0.117 108.070 0.143
201909 0.116 108.329 0.141
201912 0.132 108.420 0.160
202003 0.107 108.902 0.129
202006 0.116 108.767 0.141
202009 0.120 109.815 0.144
202012 0.138 109.897 0.165
202103 0.116 111.754 0.137
202106 0.153 114.631 0.176
202109 0.179 115.734 0.204
202112 0.204 117.630 0.229
202203 0.195 121.301 0.212
202206 0.219 125.017 0.231
202209 0.226 125.227 0.238
202212 0.234 125.222 0.246
202303 0.162 127.348 0.168
202306 0.199 128.729 0.204
202309 0.206 129.860 0.209
202312 0.237 129.419 0.241
202403 0.194 131.776 0.194

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Cerus  (STU:CU2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cerus's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.804/0.58
=3.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cerus was 14.94. The lowest was 1.95. And the median was 8.35.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cerus Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Cerus's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerus (STU:CU2) Business Description

Industry
Traded in Other Exchanges
Address
1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Cerus (STU:CU2) Headlines

No Headlines